Literature DB >> 18365537

Cell-cycle molecules in mesothelioma: an overview.

E P Spugnini1, M Campioni, A D'Avino, G Caruso, G Citro, A Baldi.   

Abstract

Cell cycle progression is mediated by a group of proteins named cyclins that activate a highly conserved family of protein kinases, the cyclin-dependent kinases (CDKs). CDKs are also regulated by related proteins called cdk inhibitors, grouped into two families: the INK4 inhibitors (p16, p15, p19 and p18) and the Cip/Kip inhibitors (p21, p27). Moreover, several tumour suppressor genes (such as Retinoblastoma gene and p53 gene) are implicated in the regulation of the molecular mechanism of cell division. Several studies report the importance of cell cycle regulator proteins in the pathogenesis and the prognosis of mesothelioma. This article will review the most recent data from the literature about the expression and the diagnostic and prognostic significance of cell cycle molecules in mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18365537

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  9 in total

1.  Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion.

Authors:  Yirong Li; Martin Ligr; James P McCarron; Garrett Daniels; David Zhang; Xin Zhao; Fei Ye; Jinhua Wang; Xiaomei Liu; Iman Osman; Simon K Mencher; Hebert Lepor; Long G Wang; Anna Ferrari; Peng Lee
Journal:  Clin Cancer Res       Date:  2011-05-23       Impact factor: 12.531

2.  1,25-dihydroxyvitamin D3 treatment delays cellular aging in human mesenchymal stem cells while maintaining their multipotent capacity.

Authors:  Barbara Klotz; Birgit Mentrup; Martina Regensburger; Sabine Zeck; Jutta Schneidereit; Nicole Schupp; Christian Linden; Cornelia Merz; Regina Ebert; Franz Jakob
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

3.  Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.

Authors:  C J Jennings; B Murer; A O'Grady; L M Hearn; B J Harvey; E W Kay; W Thomas
Journal:  Br J Cancer       Date:  2015-06-09       Impact factor: 7.640

4.  Curcumin C3 complex®/Bioperine® has antineoplastic activity in mesothelioma: an in vitro and in vivo analysis.

Authors:  Francesco Di Meo; Stefania Filosa; Michele Madonna; Gerarda Giello; Alba Di Pardo; Vittorio Maglione; Alfonso Baldi; Stefania Crispi
Journal:  J Exp Clin Cancer Res       Date:  2019-08-16

5.  Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability.

Authors:  Alessandra Verdina; Irene Cardillo; Angela Nebbioso; Rossella Galati; Simona Menegozzo; Lucia Altucci; Ada Sacchi; Alfonso Baldi
Journal:  J Transl Med       Date:  2008-05-22       Impact factor: 5.531

6.  Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations.

Authors:  Enrico P Spugnini; Stefania Crispi; Alessandra Scarabello; Giovanni Caruso; Gennaro Citro; Alfonso Baldi
Journal:  J Exp Clin Cancer Res       Date:  2008-05-19

7.  CSE1L/CAS, the cellular apoptosis susceptibility protein, enhances invasion and metastasis but not proliferation of cancer cells.

Authors:  Ching-Fong Liao; Shue-Fen Luo; Li-Tzu Li; Chuang-Yu Lin; Ying-Chun Chen; Ming-Chung Jiang
Journal:  J Exp Clin Cancer Res       Date:  2008-07-03

8.  Identification of genes down-regulated during lung cancer progression: a cDNA array study.

Authors:  Mara Campioni; Vincenzo Ambrogi; Eugenio Pompeo; Gennaro Citro; Mauro Castelli; Enrico P Spugnini; Antonio Gatti; Pierluigi Cardelli; Laura Lorenzon; Alfonso Baldi; Tommaso C Mineo
Journal:  J Exp Clin Cancer Res       Date:  2008-09-15

Review 9.  Curcumin as an Anticancer Agent in Malignant Mesothelioma: A Review.

Authors:  Alfonso Baldi; Antonio De Luca; Patrizia Maiorano; Costantino D'Angelo; Antonio Giordano
Journal:  Int J Mol Sci       Date:  2020-03-07       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.